Structural basis for recruitment of the CHK1 DNA damage kinase by the CLASPIN scaffold protein by Day, Matthew et al.
Structural basis for recruitment of the CHK1 DNA damage 
kinase by the CLASPIN scaffold protein
Article  (Published Version)
http://sro.sussex.ac.uk
Day, Matthew, Parry-Morris, Sarah, Houghton-Gisby, Jack, Oliver, Antony W and Pearl, Laurence 
H (2021) Structural basis for recruitment of the CHK1 DNA damage kinase by the CLASPIN 
scaffold protein. Structure, 29 (6). 531-539.e3. ISSN 0969-2126 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/101890/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
ArticleStructural basis for recruitment of the CHK1 DNA
damage kinase by the CLASPIN scaffold proteinGraphical abstractHighlightsd Novel crystal forms of the CHK1 kinase domain are reported
d Nucleotide-bound CHK1 structure
d Phosphorylated CLASPIN peptide-bound CHK1 structure
d CHK1-CLASPIN interaction does not affect kinase kineticsDay et al., 2021, Structure 29, 531–539
June 3, 2021 ª 2021 The Authors. Published by Elsevier Ltd.
https://doi.org/10.1016/j.str.2021.03.007Authors
Matthew Day, Sarah Parry-Morris,
Jack Houghton-Gisby,





Day et al. report the structure of a
phosphorylated CLASPIN-derived
peptide bound to CHK1 and
accompanying biochemistry that
demonstrates this interaction does not
directly affect the kinetics of the CHK1
kinase, suggesting that the role of the
conserved kinase domain phosphate




Structural basis for recruitment of the CHK1
DNA damage kinase by the CLASPIN scaffold protein
Matthew Day,1 Sarah Parry-Morris,1 Jack Houghton-Gisby,1 Antony W. Oliver,1,* and Laurence H. Pearl1,2,*
1Cancer Research UK DNA Repair Enzymes Group, Genome Damage and Stability Centre, School of Life Sciences, University of Sussex,
Falmer, Brighton BN1 9RQ, UK
2Lead contact
*Correspondence: antony.oliver@sussex.ac.uk (A.W.O.), laurence.pearl@sussex.ac.uk (L.H.P.)
https://doi.org/10.1016/j.str.2021.03.007SUMMARYCHK1 is a protein kinase that functions downstream of activated ATR to phosphorylate multiple targets as
part of intra-S and G2/M DNA damage checkpoints. Its role in allowing cells to survive replicative stress
has made it an important target for anti-cancer drug discovery. Activation of CHK1 by ATR depends on their
mutual interactionwith CLASPIN, a natively unstructured protein that interacts with CHK1 through a cluster of
phosphorylation sites in its C-terminal half. We have now determined the crystal structure of the kinase
domain of CHK1 bound to a high-affinity motif from CLASPIN. Our data show that CLASPIN engages a
conserved site on CHK1 adjacent to the substrate-binding cleft, involved in phosphate sensing in other ki-
nases. The CLASPIN motif is not phosphorylated by CHK1, nor does it affect phosphorylation of a CDC25
substrate peptide, suggesting that it functions purely as a scaffold for CHK1 activation by ATR.INTRODUCTION
Checkpoint kinase 1, or CHK1, plays a key role in the cellular
response to DNA damage at different points in the cell cycle
through its function in both the intra-S-phase checkpoint, which
allows damage to be repaired to facilitate the accurate duplica-
tion of genomes, and theG2/M checkpoint, which prevents entry
into mitosis of cells with damaged chromosomes (Smits and Gil-
lespie, 2015). Among many other targets involved in these two
checkpoint responses, CHK1 phosphorylates key residues in
the three CDC25 phosphatases, resulting in their deactivation
by subsequent degradation or export from the nucleus. This
leads to cell-cycle arrest as the phosphatases can no longer acti-
vate cyclin-dependent kinase CDK1 or CDK2, the drivers of the
cell cycle. In addition, CHK1 has other important functions in the
S phase, including a role in origin firing, fork progression,
stabilizing stalled replication forks, fork restart, and pausing
the cell cycle under conditions of replication stress (Iyer and
Rhind, 2017).
CHK1 consists of an N-terminal kinase domain (Chen et al.,
2000) joined by a flexible linker region to a C-terminal kinase-
associated (KA1) domain. As an attractive cancer drug discovery
target, many crystal structures of the CHK1 kinase domain
(CHK1-KD) have been determined bound to various fragments
and inhibitors. In all structures of CHK1-KD, whether in apo
form or with an inhibitor bound, the kinase domain is in an active
conformation with an ordered activation loop, but with a slightly
open lobe arrangement leading to the misalignment of the cata-
lytic residues. CHK1 activation occurs when key residues in the
linker region are phosphorylated by ATR (Niida et al., 2007).Structure 29, 531–539
This is an open access article under the CC BY-NThese disrupt intramolecular interactions between the kinase
and the KA1 domain (Emptage et al., 2017), and mutations that
disrupt the KA1 domain lead to constitutive activity (Gong
et al., 2015). Additional autophosphorylation of the KA1 domain
further activates the kinase (Gong et al., 2018), and there may be
a role for further phosphorylation-driven intermolecular interac-
tions with other factors.
CLASPIN was identified as an interactor with CHK1 in Xeno-
pus extracts (Kumagai and Dunphy, 2000) and was required
for the activation of CHK1 in response to DNA replication blocks
and stalled replication forks, a function that is conserved in hu-
mans (Clarke and Clarke, 2005). The interaction between
CHK1 and CLASPIN has also been demonstrated to play a role
in the checkpoint response to UV-induced DNA damage (Jeong
et al., 2003). CLASPIN is required for the ATR-dependent phos-
phorylation of CHK1 (Kumagai et al., 2004) leading to its activa-
tion, and furthermore, the ATR-dependent phosphorylation of
CHK1 has been demonstrated to be directly stimulated by
CLASPIN in an in vitro reconstituted system using recombinant
human proteins (Lindsey-Boltz et al., 2009).
CLASPIN is predicted to be largely disordered (Figure S1A),
forming a natively unfolded protein (Wright and Dyson, 2015)
with three repeated linear motifs that mediate the interaction
with CHK1 (Chini and Chen, 2006; Jeong et al., 2003; Kumagai
and Dunphy, 2003). These sites in CLASPIN have been reported
to be phosphorylated by CHK1 itself (Chini and Chen, 2006) but
also through a CHK1-independent route (Bennett et al., 2008)
that involves casein kinase 1 (CK1) (Meng et al., 2011). More
recently an additional pathway has been described in which
the three sites are phosphorylated by CDC7 (Yang et al.,, June 3, 2021 ª 2021 The Authors. Published by Elsevier Ltd. 531
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. In vitro characterization of CHK1-
CLASPIN interaction
(A) Schematic representation of CHK1 and CLAS-
PIN and the sequences of the three repeated
CHK1 binding motifs in CLASPIN. The underlined
regions correspond to the sequences used to
synthesize fluorescein-labeled peptides, and the
sequence consensus is shown. See also Figure S1.
(B) Fluorescence polarization experiments show
binding between a CHK1 construct consisting of
only the kinase domain (CHK1-KD) and the three
motifs in CLASPIN. All error bars are one standard
error of the mean.
(C) Treatment with l-phosphatase abolishes
binding, confirming that the interaction is specific
for the phosphorylated CLASPIN peptides.
(D) R129A and R162E mutations, which are in
residues involved in sulfate binding in CHK1, also
abolish interaction with the phosphorylated pep-
tides, demonstrating that this is the only site
responsible for binding to each of the individual
motifs in CLASPIN.
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OPEN ACCESS Article2019). Previous studies implicated a site in CHK1-KD, centered
around Arg-129, Thr-153, and Arg-162, required for binding to
the three phosphorylation sites in CLASPIN in immunoblot ex-
periments (Jeong et al., 2003).
Here we biochemically characterize the phosphorylation-
mediated CLASPIN-CHK1 interaction and determine the crystal
structure of a complex between CHK1-KD and a phosphorylated
CLASPIN peptide. Our results reveal the molecular details of this
interaction in the context of CHK1 activation and uncover a new
role for an evolutionarily conserved phosphate binding pocket in
the kinase domain, which is adapted to multiple functions in
different kinase families.
RESULTS
A single site in CHK1-KD can bind to the phosphorylated
CLASPIN motifs
To characterize the interactions between CHK1 and the three
repeated phosphorylation sites in CLASPIN (Figure 1A), we syn-
thesized phosphopeptides corresponding to the three different
repeats centered on pT916, pS945, and pS982, and measured
their binding to CHK1-KD using fluorescence polarization (FP).
All three peptides independently bound the kinase domain with
affinities in the high nanomolar range (Figure 1B), with the tight-
est interaction between the kinase domain and the peptide
encapsulating the pS945 site. The interaction was abrogated
when treated with l-phosphatase (Figure 1C), demonstrating
that the interaction is indeed phosphorylation dependent. Muta-
tions in residues that contribute to the binding of a sulfate ion in
the original structure of the CHK1-KD, Arg-129 and Arg-162
(Chen et al., 2000), also abolished the interaction (Figure 1D).
Crystal engineering
Analysis of CHK1-KD structures deposited in the Protein Data-
bank (PDB) reveals two different lattices in which the protein532 Structure 29, 531–539, June 3, 2021crystallizes (Figure 2A). However, at-
tempts to either soak a phosphorylated
CLASPIN peptide into crystals of CHK1-KD or co-crystallize a complex of CHK1-KD with a CLASPIN
peptide were unsuccessful, yielding crystals of CHK1 alone or
in complex with staurosporine in both of the previously observed
crystal forms. Examination of the molecular packing (Figure 2B)
in these crystal forms suggested that the region surrounding the
putative phosphate binding site was potentially occluded by
contacts with other molecules in the crystal lattice, and this
was likely to interfere with binding of a CLASPIN motif in that re-
gion (confirmed once the structure of the complex had been
determined). In an attempt to relieve this potential restriction,
we made a point mutation changing Asp-10 to an Arg residue,
distant from both the active site and the putative CLASPIN inter-
action interface, intended to disrupt a salt bridge contact in the
lattice (Figure 2C), thereby destabilizing the predominantly
observed crystal form and allowing new packing variants to be
produced.
Crystal structure of CHK1 bound to ATPgS
In an attempt to produce a CLASPIN-bound crystal structure of
CHK1-KD, various combinations of nucleotides, inhibitors, and
peptides were combined and set up in crystallization trials.
One of these attempts, where the CLASPIN peptide and ATPgS
were included, yielded a structure of the kinase domain bound to
the nucleotide alone. The kinase domain is in a conformation
similar to that seen in the two known crystal forms, with the
nucleotide binding site, activation loop, and catalytic residues
ordered and positioned in an active, but open, conformation (Fig-
ure 3A). There is clear density for the ATPgS with the ribose in a
C3-endo conformation (Figure 3B). This is in contrast to a re-
ported structure of an AMPPNP-bound complex in which the
ribose was in the C5-endo conformation and the phosphate
groups could not be seen (Chen et al., 2000). However, the co-
ordinates and diffraction data for that structure have never
been deposited in the PDB, so the reliability of that observation
cannot be ascertained. In the ATPgS complex, two magnesium
Figure 2. CHK1 lattice engineering
(A) Summary of CHK1-KD structures in the PDB; cell dimensions are averages across the indicated number of structures in each case.
(B) The asymmetric unit of PDB entry 1NVR, representative of the predominant lattice, contains a single copy of the kinase domain, shown in yellow, with
symmetry-related molecules shown here in gray. The phosphorylated CLASPIN binding site is marked with a sulfate ion in the structure, while the active site is
occupied by the presence of staurosporine.
(C) Details for the salt bridge between Asp-10 and Arg-181 that is disrupted by the D10R mutation shown alongside its location with respect to the active site,
marked by staurosporine, and putative CLASPIN interaction surface, marked with the sulfate ion.
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OPEN ACCESSArticleions, chelated by residues Asn-135 and Asp-148, can be seen in
the active site balancing the charge on the phosphate groups of
the nucleotide. Whereas the phosphate groups can be unambig-
uously placed in this structure, the g-phosphate is not positioned
in the presumed correct location for catalysis, with the catalytic
Asp-130 residue situated 8 Å from the bridging thioether of the
ATPgS (Figure 3C). This is not dissimilar to CDK2, where struc-
tures of several activation states are known, including both an
active open state (Russo et al., 1996), where the activation
loop is ordered but the catalytic aspartate is similarly distant
from the nucleotide as for this structure, and an active closed
confirmation (Bao et al., 2011), representing the transition state
of the enzyme. The conformation of CHK1 seen here may be
due to constraints imposed by the crystal lattice or potentially
represents a nucleotide-bound open conformation formed prior
to substrate peptide binding, which might promote full closure of
the active site to bring the aspartate residue into the correct po-
sition for catalysis to occur. A substrate peptide-bound structure
would help to distinguish between these possibilities.
Crystal structure of CHK1 bound to CLASPIN
A further trial, where the kinase domain was mixed with the
CLASPIN peptide and the broad-spectrum ATP-competitive ki-
nase inhibitor staurosporine, produced a structure in which
both the inhibitor and the peptide were present. There are two in-
dependent copies of the kinase domain in the asymmetric unit of
this crystal lattice, and while both of the CHK1 molecules are
able to accommodate the CLASPIN peptide, in one of the chainsthe peptide is constrained by the lattice and likely adopts an arti-
factual conformation where the peptide interacts with multiple
CHK1 molecules (Figure S2). The CLASPIN peptide bound to
the other chain adopts a position and conformation situated be-
tween, and making interactions with, the C helix and the activa-
tion loop of a single kinase domain (Figure 4A), with density for
the peptide visible in an omit map (Figure 4B).
Notably, the overall positioning of the kinase domain lobes
with respect to each other, and the active-site architecture, is
the same as previously determined apo or inhibitor-bound struc-
tures (Figure 4C), with an overall root-mean-square deviation of
0.252 Å for all protein atoms from a staurosporine-bound struc-
ture (Zhao et al., 2002). This suggests that CLASPIN binding
does not play a significant role in aligning the active-site residues
into a catalytically active conformation.
The phosphorylated state of the CLASPIN peptide is recog-
nized by the side chains of CHK1 Lys-54, Arg-129, Thr-153,
and Arg-162, coordinating the phosphate group of CLASPIN
pSer-945, with additional H-bond interactions between the
main-chain carbonyl of CLASPIN pSer-945 and the side chain
of CHK1 Arg-162 (Figure 4D). Specificity for the CLASPIN
sequence beyond the phosphorylation is provided by a series
of predominantly hydrophobic interactions (Figure 4E). Leu-943
of CLASPIN sits between the side chains of CHK1 Lys-53, Lys-
54, and Cys-57, while CLASPIN Leu-940, Leu-941, and Phe-
948 protrude into a hydrophobic groove on the surface of the
kinase domain lined by the side chains of CHK1 Met-61, Val-
154, Tyr-157, and Arg-162.Structure 29, 531–539, June 3, 2021 533
Figure 3. Nucleotide-bound CHK1 structure
(A) Superposition of the ATPgS-bound CHK1
structure (yellow) with an apo CHK1 structure, 1IA8
(gray); both the overall arrangement of the N and C
kinase lobes and the details of key active-site
residues are identical between the two models.
(B) 2mFo-DFc map showing electron density at 2s
for ATPgS in the structure.
(C) Details of the distance between the catalytic
Asp-130 residue and the g-phosphate of
the ATPgS.
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OPEN ACCESS ArticleTo validate the CLASPIN binding mode seen in the crystal
structure, a peptide with a point mutation in the phenylalanine
conserved between the three motifs, and shown from the crystal
structure to be important for the interaction, was synthesized,
and its binding to CHK1-KD was measured using FP. The muta-
tion was found to significantly lower the affinity of the interaction
in the FP assay (Figure 4F).
CLASPIN binding is uncoupled from CHK1 regulation
The position of the CLASPIN binding site on CHK1 that our study
reveals is distant from the proposed CHK1-KA1 domain binding
site based on models derived from the MARK1 kinase structure
(Emptage et al., 2018) (Figure 5A), but in a similar location
compared with the cyclin binding site in CDKs (Russo et al.,
1996). This suggests that CLASPIN binding would be unaffected
by the KA1 domain-regulated activation state of CHK1. To test
this, we purified full-length CHK1, treated it with l-phosphatase
to removeany activating phosphorylation, andmeasured its affin-
ity for theCLASPINphosphopeptide inanFPassay (Figure5B).As
predicted, the CLASPIN peptide still bound KA1-autoinhibited
CHK1, but with 2-fold lower affinity than for CHK1-KD, indicating
some negative cooperativity between KA1-domain andCLASPIN
binding. However, the relative weakness of the effect suggests
that it is unlikely to be biologically significant.
CLASPIN binding does not affect CHK1 activity
The coincidence of the CLASPIN binding site in CHK1with cyclin
binding to CDKs suggests that CLASPIN, like cyclins, might
modulate the affinity of the kinase for its substrate and/or affect
its catalytic activity. To test this, we used FP to determine the af-534 Structure 29, 531–539, June 3, 2021finity of a CDC25C substrate peptide for
CHK1-KD in the presence or absence of
the pS945 CLASPIN peptide, but saw no
significant difference (Figure 5C), sug-
gesting that the CHK1-CLASPIN interac-
tion does not modulate the affinity of
CHK1-KD for substrate.
To determine whether CLASPIN bind-
ing has an allosteric effect on CHK1
kinase activity, we used an NADH-
coupled ATPase assay to determine the
rate of ATP turnover in the presence of a
substrate peptide corresponding to the
CHK1 phosphorylation site in CDC25C.
Under the conditions tested, the rate of
the reaction was 2.25 mol min1 mol1for the full-length kinase and 7.73 mol min1 mol1 for the kinase
domain alone. For both full-lengthCHK1andCHK1-KD, the addi-
tion of the CLASPIN pS945 peptide had no effect on the rate of
ATP turnover of the reaction in the presence of the CDC25C pep-
tide (Figure 5D). To show that theATP turnovermeasuredwas the
result of the phosphorylation of Ser-216 in the CDC25C peptide,
rather than some other activity, a CDC25C substrate peptide in
which Ser-216 was replaced with an alanine was used, which
showed no activity in the assay. We also looked at whether the
CLASPIN peptide itself could be phosphorylated by CHK1, as
has been suggested (Chini and Chen, 2006), but saw no stimula-
tion of ATP turnover by CHK1 in the presence of the unphos-
phorylated S945 CLASPIN peptide (Figure 5E).
DISCUSSION
The results presented here provide a reliablemodel for the nucle-
otide-bound state of CHK1-KD and reveal the molecular basis of
the phosphorylation-dependent interaction between CHK1 and
CLASPIN. Our data show that CLASPIN binding has no signifi-
cant direct effect on the regulation or kinase activity of CHK1,
but suggest that CLASPIN acts as a pure scaffold, facilitating
the recruitment of CHK1 into a larger complex in which it can
be activated through phosphorylation by ATR, downstream of
DNA damage.
The interactions of the bound CLASPIN motif with CHK1
explain the pattern of small hydrophobic residues at positions
1, 2, 4, and 5 relative to the phosphorylated Ser/Thr,
and a glycine at +1 and phenylalanine at +3, all of which are
very strongly conserved in the three repeats of this motif that
Figure 4. CLASPIN-bound CHK1 structure
(A) Structure of a CLASPIN pS945 peptide (purple) bound to CHK1-KD (yellow) with staurosporine bound in the active site. See also Figure S2.
(B) A 2mFo-DFc omit map showing density at 2s for the CLASPIN peptide in the structure.
(C) Superposition of the CLASPIN pS945 CHK1 structure (yellow) with a staurosporine-bound CHK1 structure 1NVR (gray). The overall arrangements of the N and
C kinase lobes are identical between the two models.
(D) Details of the interaction with the phosphate group of the bound CLASPIN peptide. Residues in the peptide are labeled in bold.
(E) Details of the hydrophobic interactions made between the kinase domain and the CLASPIN peptide.
(F) Fluorescence polarization experiments show that binding between the CLASPIN peptide and CHK1 can be abrogated by a mutation in the CLASPIN
sequence. All error bars are one standard error of the mean.
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OPEN ACCESSArticleoccur throughout the vertebrates. As our structural and
biochemical data show that a single copy of this motif is suffi-
cient for a high-affinity interaction with a unique site on CHK1,
the apparent biological need for a triple tandem array of these
motifs in CLASPIN is far from clear. Pull-down studies of Xeno-
pus CLASPIN, in which the third repeat is less strongly
conserved, indicated some possible cooperativity in CHK1 bind-
ing between the first two sites (Kumagai and Dunphy, 2003), fa-voring binding of multiple CHK1 molecules to a single CLASPIN.
Focal accumulation of CHK1 at sites of ATR activation can be
observed in cells following DNA damage (Bigot et al., 2019),
and recruitment of multiple CHK1 molecules by each CLASPIN
might be a means of generating a high concentration of CHK1
activity at sites of DNA damage.
Clustering of CHK1 molecules by CLASPIN could also play a
role in the second stage of the CHK1 kinase activation process,Structure 29, 531–539, June 3, 2021 535
Figure 5. CHK1-CLASPIN interaction does not directly affect kinase activity
(A) Model for the interaction of the KA1 domain (orange) with the kinase domain (yellow) for CHK1 produced by superposing both the KA1 domain and the
CLASPIN-bound kinase domain on the KA1-autoinhibited MARK1 kinase structure 6C9D. Fluorescence polarization experiments showing CLASPIN peptide
interactions with full-length CHK1 or a CHK1 construct consisting of only the kinase domain are presented. The CLASPIN peptide binds with comparable affinity
to both constructs.
(B) Fluorescence polarization experiments showing affinities of the CLASPIN pS945 peptide for full-length CHK1 or the CHK1 kinase domain alone. The presence
of the KA1 regulatory region of CHK1 has a minimal effect on the affinity for the CLASPIN peptide. All error bars are one standard error of the mean.
(C) Fluorescence polarization experiments showing CDC25C substrate peptide interactions with a CHK1 construct consisting of only the kinase domain, in the
presence or absence of the CLASPIN pS945 peptide. The presence of the CLASPIN peptide has no significant effect on the affinity of the kinase for the substrate
peptide.
(legend continued on next page)
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Figure 6. Varied roles of the conserved
phosphate binding pocket
(A) Superposition of the kinase domains and in-
teracting regions of CDK2 (pink), GSK3b (cyan),
and CHK1 (yellow) showing location of the
conserved phosphate binding pocket, marked
with a phosphate group from the CHK1-CLASPIN
structure presented here.
(B–D) Details of the interaction with phosphory-
lated residues in CDK2 (B), GSK3b (C), and CHK1
(D). The LRP6 inhibitor peptide bound to GSK3b is
shown in pink and the CLASPIN scaffold peptide
bound to CHK1 in purple.
ll
OPEN ACCESSArticlewhich requires autophosphorylation at two consensus CHK1-
phosphorylation motifs and at least one non-consensus site
within the KA1 domain, subsequent to phosphorylation by ATR
(Gong et al., 2018; Kasahara et al., 2010; Okita et al., 2012). Au-
tophosphorylation mediated by phosphorylation-dependent
clustering downstream of phosphorylation by ATM also under-
lies activation of the other checkpoint kinase, CHK2 (Ahn et al.,
2002; Oliver et al., 2006). However, the two processes are mech-
anistically distinct, as CHK1 autophosphorylation occurs in an
ancillary domain and may be partly intramolecular (Okita et al.,
2012), while trans-autophosphorylation of CHK2 and related ki-
nases occurs within the kinase domain itself and is strictly inter-
molecular (Oliver et al., 2007; Pike et al., 2008).
Analternative function for the tandemmotifsofCLASPIN isasan
internal scaffold, whereby prior phosphorylation of one motif that
engageswith theCLASPINbindingsiteonCHK1facilitatesbinding
of an adjacent unphosphorylated motif to the active site of CHK1
as a substrate, by increasing its local concentration. Phosphoryla-
tion of CLASPIN by CHK1 in vitro has been reported (Chini and
Chen, 2006), but subsequent studies show that CHK1 is not
required for CLASPIN phosphorylation in vivo (Bennett et al.,
2008), where this function is fulfilled by CK1g1 (Meng et al.,
2011) and CDC7 (Yang et al., 2019). Our in vitro data show that(D) Reaction rates for NADH-coupled assays showing ATP turnover by either full-length CHK1 or a CHK1 co
presence of increasing concentrations of the CLASPIN pS945 peptide. Taken together with (C), these data sh
CHK1 kinase function. See also Figures S3A–S3D.
(E) NADH-coupled ATPase assay for CHK1-KD incubated with a CDC25C substrate, mutant S216A CDC25
data show that the CLASPIN peptide itself is not a substrate for CHK1 kinase, contrary to previous suggestan isolated unphosphorylated CLASPIN
motif displays negligible affinity for CHK1
and no significant activity as a kinase sub-
strate. Althoughwe cannot completely rule
out the possibility that CHK1 might phos-
phorylate a longer CLASPIN peptide
spanning two or more motifs, where one
is already phosphorylated, the lack of
even a weak affinity or activity for the iso-
lated unphosphorylated CLASPIN CHK1-
binding motif argues against this.
CLASPIN utilizes a conserved
phosphate binding pocket
The site occupied by the phosphorylated
Ser/Thr in CLASPIN’s CHK1 binding mo-tifs is a phosphate binding pocket that serves at least four
different functions across the different kinases within which it is
evolutionarily conserved (Figure 6). In all cases the residues
that coordinate a bound phosphate group are highly conserved,
but the rest of the binding site that provides the larger recognition
process in each case is not. The most widely observed role for
this site is to bind to the side chain of a phosphorylated threonine
within the activation segment of the kinase and bridge it to the
C helix within the N-terminal lobe (Endicott et al., 2012). Thus,
for example, in CDK2, the side chains of Arg-50, Arg-126, and
Arg-150 coordinate the phosphate group of pThr-160 of CDK2
(Figure 6B), thereby stabilizing the active conformation of the
enzyme (Bao et al., 2011). The equivalent site in GSK3b (Arg-
96, Arg-180, and Lys-205) functions in the specific recognition
of ‘‘primed’’ substrates by coordinating the phosphate group
on already phosphorylated residues within the substrate,
positioned four residues downstream of the residue being
phosphorylated, and thereby greatly enhances their affinity for
the kinase and the efficiency of their phosphorylation (Dajani
et al., 2001). This site is also used to regulate GSK3b kinase
activity by facilitating binding of phosphorylated residues in
inhibitory sequences, such as pSer-9 in the autoinhibitory N ter-
minus of GSK3b itself, or pSer-1607 in low-density lipoproteinnstruct consisting of only the kinase domain in the
ow that CLASPIN binding has no allosteric effect on
C substrate, and CLASPIN S945 substrate. These
ions (Chini and Chen, 2006). See also Figure S3E.
Structure 29, 531–539, June 3, 2021 537
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OPEN ACCESS Articlereceptor-like protein 6 (LRP6) (Stamos et al., 2014) (Figure 6C),
so that the upstream sequence occupies the active site and pre-
vents substrate access. The structure of the CLASPIN-CHK1
complex described here (Figure 6D) adds a hitherto unknown
role for this site, in providing a phosphorylation-dependent scaf-
fold interaction that facilitates recruitment of the kinase to a spe-
cific cellular location.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
WTandmutant humanCHK1 proteins were recombinantly expressed in SF9 insect cells. Cells were grown in 400mL of Sf-900 II SFM
media (Thermofisher, UK) at 27C shaking at 140 RPM in 2 L bottles. Cells for expression were typically amplified by splitting at a
density of 5 3 105 cells ml1, once a density of 4 3 106 cells ml1 had been reached, and infections with virus for expression
were done once the cells had reached a density of 1.5 3 106 cells ml1, with a multiplicity of infection of 5, before harvesting three
days later.
METHOD DETAILS
Generation of bacmids and cell culture
Coding sequences for Strep and HIS taggedCHK1 full length and Kinase domain alone were synthesised and ligated into pFastBAC1
(Thermofisher, UK). Mutationsweremade using aQ5Site-DirectedMutagenesis Kit (NEB, Hitchin, UK). Plasmidswere transformed
into DH10BAC cells (Fisher Scientific, UK) and bacmids were purified by standard procedures. Bacmids were transfected into SF9
cells (Thermofisher, UK) using Cellfectin II reagent (Fisher Scientific, UK), before viral amplification and protein expression.
Protein expression and purification
Recombinant full length CHK1, or kinase domain alone (CHK1-KD), was produced by infecting Sf9 cells with a baculovirus coding for
a construct containing STREP-(3C)-CHK1-HIS or STREP-(3C)-CHK1(1–290)-HIS respectively. Cell pellets were re-suspended in lysis
buffer containing 50mM HEPES pH 7.5, 200mM NaCl, 0.5mM TCEP, and supplemented with 10 U DNASE Turbo and protease in-
hibitor tablets, then disrupted by sonication, and the resulting lysate clarified by centrifugation at 40,000 x g for 60 min at 4C. The
supernatant was applied to a 5mL HiTrap TALON crude column (GE Healthcare, Little Chalfont, UK), washed first with buffer con-
taining 50mM HEPES pH 7.5, 500mM NaCl, 0.5mM TCEP, followed lysis buffer supplemented with 10 mM 10mM imidazole, with
any retained protein then eluted by application of the same buffer but now supplemented with 250mM imidazole. The eluted protein
was diluted with lysis buffer before application to a 5mLHiTrap STREP column (GEHealthcare, Little Chalfont, UK), washed with lysis
buffer and eluted using buffer supplemented with 2 mM Desthiobiotin.
For FP experiments, a Superdex 75 16/60 size exclusion column (GE Healthcare, Little Chalfont, UK) was used to purify the protein
to homogeneity in 25mM HEPES pH 7.5, 200mM NaCl, 1mM EDTA, 0.25mM TCEP, 0.02% (v/v) Tween 20.
For crystallographic studies, the N-terminal STREP tag was removed by incubation with GST-3C protease (in house) for 12 hr at
4C. A Superdex 75 16/60 size exclusion column (GE Healthcare, Little Chalfont, UK) was used to purify the kinase domain to homo-
geneity in 10mM HEPES pH 7.5, 200mM NaCl, 0.5mM TCEP.
Fluorescence polarisation experiments
Fluorescein-labelled (Flu-pT916 Flu-GGMDELLDLC(pT)GKFTSQ, Flu-pS945 Flu-GGMEELLNLC(pS)GKFTSQ, Flu-pS945_F948A
Flu-GGMEELLNLC(pS)GKATSQ and Flu-pS982 Flu-GGMEEALALC(pS)GSFPTD) or CY5-labelled (Cy5-CDC25C-S216 Cy5-CGYG
GLYRSPSMPENLNRPRLK) peptides (Peptide Protein Research Ltd, Bishops Waltham, UK) at a concentration of 100nM, or for
the double peptide experiment 200 nM Cy5-CDC25C and 1000 nM CLASPIN pS945, were incubated at room temperature with
increasing concentrations of CHK1-KD, or lambda phosphatase treated full length CHK1 in 25mM HEPES pH 7.5, 200mM NaCl,
1mM EDTA, 0.25mM TCEP, 0.02% (v/v) Tween 20 in a black 96-well polypropylene plate (VWR, Lutterworth, UK). Incubation with
Lambda phosphatase (NEB, Hitchin, UK) supplemented with 1 mMMnCl2 was used to remove the phosphorylation on the peptides.
Fluorescence polarisation was measured in a POLARstar Omega multimode microplate reader (BMG Labtech GmbH, Offenburg,
Germany). Binding curves represent the mean of 3 independent experiments, with error bars of 1 standard deviation.
Crystallography
The pure CHK1-KD was mixed with a fifty molar excess of ATPgS (Sigma-Aldrich, Gillingham, UK) and a five molar excess of both a
substrate peptide corresponding to residues 210–227 of CDC25 (GLYRSPSMPENLNRPRLK) and a pS945 CLASPIN peptideStructure 29, 531–539.e1–e3, June 3, 2021 e2
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OPEN ACCESS Article(MEELLNLC(pS)GKFT(pS)QD) (Peptide Protein Research Ltd, Bishops Waltham, UK) prior to concentration to 8 mg/mL for use in
crystallisation trials. Crystals grew in condition PACT H11 (200 mM Sodium citrate tribasic dihydrate, 100 mM Bis-Tris propane
pH 8.5 and 20%w/v PEG 3350) and following further optimisation of this condition single crystals were looped, soaked and cryopro-
tected in well solution supplemented with 30% (v/v) Ethylene Glycol before flash freezing in liquid nitrogen.
Staurosporin (NEB, Hitchin, UK) and the pS945 CLASPIN peptide (MEELLNLC(pS)GKFT(pS)QD) (Peptide Protein Research Ltd,
Bishops Waltham, UK) were mixed with the pure CHK1-KD at two and five molar excess respectively prior to concentration to
8 mg/mL for use in crystallisation trials. Crystals grew in condition PACT F11 (200 mM Sodium citrate tribasic dihydrate, 100 mM
Bis-Tris propane pH 6.5 and 20% w/v PEG 3350) and following further optimisation of this condition single crystals were looped,
soaked and cryoprotected in well solution supplemented with 30% Ethylene Glycol and 10 mM peptide before flash freezing in liquid
nitrogen. Data were collected on beamline I24 at the Diamond Synchrotron Lightsource and the structure was determined using
PHASER (McCoy, 2017) to perform molecular replacement with PDB 1IA8 as a search model before refinement using the PHENIX
software package (Headd et al., 2012). The structure was edited between refinements using COOT (Emsley et al., 2010) and the
model quality and results of individual rebuilding/refinement cycles were evaluated using Molprobity (Chen et al., 2010) throughout
the process.
Generation of protein structure figures
All figures were produced using PyMOL (v 2.2.2, Schrodinger LLC). For Figure 5A the CLASPIN bound kinase domainmodel from this
paper, and the CHK1 KA1 domain structure (PDB 5WI2) were superposed on the KA1-autoinhibited MARK1 kinase structure (PDB
6C9D). For Figure 6A the kinase domains and interacting regions from CDK2 (PDB 1JST) and GSK3b-LRP6 complex (PDB 4NM7)
were superposed onto the CHK1-CLASPIN structure.
ATPase assay
CHK1, to a concentration of 100 nM for the kinase domain or 200 nM for full length CHK1, was added to reaction mixtures containing
Pyruvate Kinase and Lactic Dehydrogenase enzymes (Sigma-Aldrich, Gillingham, United Kingdom) with 0.010–0.016, and 0.015–
0.023 units of activity respectively in 25 mM HEPES pH 7.5, 150 mM NaCl, 0.5mM TCEP, 0.5 mM PEP, 0.5 mM NADH, 1 mM
ATP with 0.5 mM CDC25C (210–227) peptide (GLYRSPSMPENLNRPRLK) or CDC25C S216A (210–227) peptide (GLYRSPSM-
PENLNRPRLK) or CLASPIN S945 peptide (MEELLNLCSGKFTSQ) and with or without CLASPIN pS945 peptide (MEELLNLC(pS)
GKFTSQ).(Peptide Protein Research Ltd, Bishops Waltham, UK) at different concentrations in a Thermoscientific 96 well UV
microplate (Fisher scientific, Loughborough, UK). The plates were incubated at 25C and absorbance at 340 nm was measured in
a POLARstar Omega multimode microplate reader (BMG Labtech GmbH, Offenburg, Germany) at intervals of 30 s.
QUANTIFICATION AND STATISTICAL ANALYSIS
Protein disorder prediction
The amino acid sequence was submitted to the SPOT-Disorder-single online server (Hanson et al., 2019).
Fluorescence polarisation experiments
All data were fitted by non-linear regression, to a one site – specific binding model in Prism 6 for Mac OS X (v 6.0d, GraphPad Soft-
ware) in order to calculate the reported disassociation constants (Kd).
RMSD calculations
Superposition and RMSD calculations were performed in PyMOL (v 2.2.2, Schrodinger LLC).
ATPase assay
All data were fitted by linear regression in Prism 6 for Mac OS X (v 6.0d, GraphPad Software) in order to calculate the reported rates.
For Figure 5D the fitted data can be seen in Figure S3 along with residual plots for the fitted lines for this data and Figure 5E.e3 Structure 29, 531–539.e1–e3, June 3, 2021
